ENZO BIOCHEM INC (ENZ) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:ENZ - US2941001024 - Common Stock
ENZ Key Statistics, Chart & Performance
The current stock price of ENZ is 0.3138 USD. In the past month the price decreased by -35.96%. In the past year, price decreased by -71.21%.
ENZ Latest News, Press Relases and Analysis
ENZ Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 11.55 | 100.41B | ||
| CI | THE CIGNA GROUP | 9.63 | 73.08B | ||
| LH | LABCORP HOLDINGS INC | 16.92 | 22.19B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 119.97 | 22.07B | ||
| DGX | QUEST DIAGNOSTICS INC | 18.83 | 20.44B | ||
| GH | GUARDANT HEALTH INC | N/A | 13.56B | ||
| HIMS | HIMS & HERS HEALTH INC | 69.46 | 8.54B | ||
| DVA | DAVITA INC | 12.92 | 8.42B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 35.2 | 6.47B | ||
| CHE | CHEMED CORP | 19.9 | 6.20B | ||
| RDNT | RADNET INC | 210.55 | 6.17B | ||
| OPCH | OPTION CARE HEALTH INC | 20.77 | 4.91B |
Related stock screener links
About ENZ
Company Profile
Enzo Biochem, Inc. is an integrated diagnostics, clinical lab, and life sciences company, which engages in the manufacture, development and market of products and tools for clinical research, translational research, drug development and bioscience research. The company is headquartered in Farmingdale, New York and currently employs 125 full-time employees. The firm's primary business is conducted through its Life Sciences division, Enzo Life Sciences, which is focused on labeling and detection technologies from DNA to whole cell analysis, including a comprehensive portfolio of thousands of products, including antibodies, genomic probes, assays, biochemicals, and proteins. Its products are used to label, detect and visualize a biological target of interest in drug discovery exploration and drug development process development. The Company’s proprietary products and technologies play central roles in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. The firm monetizes its technology primarily via sales through its global distribution network and licensing. The firm conducts its research and other product development efforts through internal research and collaborative relationships.
Company Info
ENZO BIOCHEM INC
60 Executive Blvd
Farmingdale NEW YORK 10022 US
CEO: Elazar Rabbani
Employees: 125
Phone: 15167555500
ENZO BIOCHEM INC / ENZ FAQ
What does ENZO BIOCHEM INC do?
Enzo Biochem, Inc. is an integrated diagnostics, clinical lab, and life sciences company, which engages in the manufacture, development and market of products and tools for clinical research, translational research, drug development and bioscience research. The company is headquartered in Farmingdale, New York and currently employs 125 full-time employees. The firm's primary business is conducted through its Life Sciences division, Enzo Life Sciences, which is focused on labeling and detection technologies from DNA to whole cell analysis, including a comprehensive portfolio of thousands of products, including antibodies, genomic probes, assays, biochemicals, and proteins. Its products are used to label, detect and visualize a biological target of interest in drug discovery exploration and drug development process development. The Company’s proprietary products and technologies play central roles in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. The firm monetizes its technology primarily via sales through its global distribution network and licensing. The firm conducts its research and other product development efforts through internal research and collaborative relationships.
What is the stock price of ENZO BIOCHEM INC today?
The current stock price of ENZ is 0.3138 USD. The price decreased by -17.77% in the last trading session.
Does ENZO BIOCHEM INC pay dividends?
ENZO BIOCHEM INC (ENZ) has a dividend yield of 31.87%. The yearly dividend amount is currently 0.
What is the ChartMill rating of ENZO BIOCHEM INC stock?
ENZ has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of ENZO BIOCHEM INC (ENZ) based on its PE ratio?
ENZO BIOCHEM INC (ENZ) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.37).
What is the next earnings date for ENZ stock?
ENZO BIOCHEM INC (ENZ) will report earnings on 2025-06-11.
ENZ Technical Analysis
ENZ Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ENZ. While ENZ seems to be doing ok healthwise, there are quite some concerns on its profitability.
ENZ Financial Highlights
Over the last trailing twelve months ENZ reported a non-GAAP Earnings per Share(EPS) of -0.37. The EPS decreased by -430.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.57% | ||
| ROE | -45.72% | ||
| Debt/Equity | 0 |